* If you want to update the article please login/register
Background The most appropriate radiotherapy dose for locally advanced esophageal squamous cell carcinoma in endemic areas treated with neoadjuvant concurrent chemotherapy is uncertain. Methods of Eligibility The Taiwan Cancer Registry identified eligible patients diagnosed between 2010 and 2019 in Taiwan. To strike a balance between visible potential confounders and non-observable confounders, we used propensity score weighting. When comparing high dose and low dose radiotherapy, the hazard ratio of death was determined.
Source link: https://europepmc.org/article/MED/PMC9700542
Background The most effective radiotherapy dose for locally advanced esophageal squamous cell carcinoma in endemic areas treated with neoadjuvant concurrent chemotherapy is uncertain. Methods of Inclusion eligible patients diagnosed between 2010 and 2019 were identified by the Taiwan Cancer Registry. When comparing high dose and low dose radiotherapy, the hazard ratio of death was calculated. Conclusions: We found no significant difference in overall survival between high and low radiotherapy doses in this population-based survey from an endemic region.
Source link: https://europepmc.org/article/MED/36434304
The most common treatment for locally diagnosed esophageal squamous cell carcinoma patients is Neoadjuvant chemoradiotherapy followed by surgery. Methods in 8 pre- and 7 post-neoCRT ESCC samples from 8 male patients were performed by single-cell RNA sequencing to determine the neoCRT-driven cellular and molecular profiles. In pre-neoCRT intermediate activated/exhausted CD8+ T cells, the correlation between CD8+ T cells' cytotoxicity and expression of checkpoint molecules was apparent. Maturation of cDC1s and expression of M2 macrophage markers increased, while the number of cDC2s decreased after neoCRT. Pre-neoCRT CD8+ T cells and macrophages have been found in a significant decline in these cells and macrophages after neoCRT, as well as a dramatic decline of them after neoCRT's response. Interpretation The complete review of the neoCRT-related immune changes provides further insight into the underlying immunologic pathways connected to ESCC's neoCRT-related immune responses, which may help with the development of immune-strategies for improving ESCC treatment.
Source link: https://europepmc.org/article/MED/PMC9699982
Neoadjuvant chemoradiotherapy followed by surgery is the most common treatment for locally diagnosed resectable squamous cell carcinoma patients. Methods 8 pre- and 7 post-neoCRT ESCC samples from 8 male patients were analyzed by single-cell RNA sequencing to determine the neoCRT-driven cellular and molecular dynamics. In pre-neoCRT intermediate activated/exhausted CD8 + T cells, the association of CD8 + T cells' cytotoxicity and expression of checkpoint molecules was prominent. Maturation of cDC1s and M2 macrophage markers increased, while the number of cDC2s decreased after neoCRT. cient response and improved neoCRT CD8+ T cells and macrophages were found in higher amounts in immune-related pathways in pre-neoCRT CD8+ T cells and macrophages, as well as a dramatic decrease of them after neoCRT. Interpretation (I) Our comprehensive review of the neoCRT-related immune responses to neoCRT-related immunogenic pathways provides deeper insight into the underlying immunological pathways associated with ESCC's neoCRT-related immune responses, which may help in the future design of immune-targeted therapy for improving ESCC treatment.
Source link: https://europepmc.org/article/MED/36434949
Importance Neoadjuvant therapy is rarely associated with a complete histopathologic response in patients with pancreatic duct carcinoma cancer adenocarcinoma, but it does result in regional nodal disease declines. Objects To investigate the prognostic value of AT in patients with node-negative disease after NAT and to identify risk factors associated with progression-free and overall survival. Patients with localized PDAC treated with preoperative therapy and subsequent surgical resection between 2010 and 2019, with N0 disease in final histopathology. Following all planned chemotherapy and approximately 4 to 5 weeks before scheduled surgery, patients receiving NART, chemotherapy regimens were gemcitabine or 5-fluoururacil-based chemotherapy regimens, as well as stereotactic body radiotherapy or intensity-modulated radiation therapy. Adjuvant therapy, whether gemcitabine-based therapy or FOLFIRINOX, was used; when used, adjuvant radiation was commonly administered as either SBRT or IMRT. The association of AT with PFS and OS was investigated in the overall cohort and in different subgroups. According to PNI, LVI, and poorly differentiated tumors, chronic PFS and OS in N0 disease were independently associated with higher PFS and OS in N0 disease after NAT, with hazard ratios of 2. 04 and 1. 68, 1. 47 and 1. 54 versus 1. 90 and 1. 98 respectively, respectively. After NAT and surgical resection, the findings of this cohort study suggest a survival benefit for AT in patients with N0 disease.
Source link: https://europepmc.org/article/MED/36416848
Historically poor in patients with resected esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy is particularly painful in those who were identified as ypT3/T4 and/or ypN+. This review explored whether adjuvant chemoradiotherapy was associated with improved clinical outcomes in these patients. Methods We found patients with esophageal squamous cell carcinoma staged as ypT3/T4 and/or ypN+ after being treated with neoadjuvant chemoradiotherapy and esophagectomy between the years 2013 and 2019. Although a greater number of lymph nodes removed was clearly associated with improved overall longevity, a greater number of lymph nodes were still associated with decreased overall survival and a trend toward worse recurrence-free survival. After receiving chemoradiotherapy and radical surgery, adjuvant CRT was shown by this study to be a significantly increased life expectance and lower risk of recurrence in esophageal squamous cell carcinoma patients staged as ypT3 and/or ypN+.
Source link: https://europepmc.org/article/MED/36428557
This research sought to characterize the intestinal microbiome of patients with esophageal squamous cell carcinoma (Esophageal squamous cell carcinoma) and to identify changes in the patient's composition during therapy. We found changes in the gut microbiome in 21 patients with esophageal squamous cell carcinoma in 21 consecutive patients with esophageal squamous cell carcinoma at five separate time points, ranging from neoadjuvant therapy to postoperative surgery. Results Before treatment, participants with esophageal squamous cell carcinoma had different alpha and beta variations in comparison to healthy controls. Conclusions: With surgical intervention, the intestinal microbiome in patients with esophageal squamous cell carcinoma is altered.
Source link: https://europepmc.org/article/MED/36401664
This study was designed to determine the survival benefits of a number of lymph nodes dissection in patients receiving neoadjuvant chemotherapy for esophageal squamous cell carcinoma. We retrospectively reviewed the clinical pathological findings and survival of 407 ESCC patients who underwent esophagectomy after NCT between January 2015 and December 2016. Both the patients had a distinct non-linear relationship between LND and the hazard ratios for OS and DFS. Patients with nodal metastases who have nodal metastases - with nodal metastases. After NCT, a degree of lymphadenectomy was helpful in reducing 5-year OS and DFS for ESCC patients with nodal metastases.
Source link: https://europepmc.org/article/MED/36385581
The aim of this report is to determine the long-term prognostic value of CRM status with various CRM metrics in esophageal squamous cell carcinoma. The influence of CRM status on long-term survival of 838 patients with resected pT3 tumors and no neoadjuvant therapy was determined by CAP and RCP criteria. Positive CRM was discovered in 59 patients according to the CAP guidelines and 317 patients according to RCP criteria. Patients with CRM > 1 mm had improved prognosis than patients with CRM > 0-1 mm in the pN0 subgroup. In a pN2-subgroup, patients with CRM 0 mm had a shorter outcome than patients with CRM > 0 mm. Conclusions The CRM status is a significant prognostic factor in ESCC patients, but the benefit was limited to patients with or without less lymph node metastasis.
Source link: https://europepmc.org/article/MED/36384463
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions